AU2014399919B2 - Specific biomarker set for non-invasive diagnosis of liver cancer - Google Patents

Specific biomarker set for non-invasive diagnosis of liver cancer Download PDF

Info

Publication number
AU2014399919B2
AU2014399919B2 AU2014399919A AU2014399919A AU2014399919B2 AU 2014399919 B2 AU2014399919 B2 AU 2014399919B2 AU 2014399919 A AU2014399919 A AU 2014399919A AU 2014399919 A AU2014399919 A AU 2014399919A AU 2014399919 B2 AU2014399919 B2 AU 2014399919B2
Authority
AU
Australia
Prior art keywords
biomarker
antibodies
hcc
auto
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014399919A
Other languages
English (en)
Other versions
AU2014399919A1 (en
Inventor
Cornelia Wing Yin Man
Benjamin Chi Yin Wai
Norman Fung Man Wai
Bing Lou Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragon Victory Development Ltd
Original Assignee
Dragon Victory Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/321,870 external-priority patent/US9885718B2/en
Priority claimed from US14/321,867 external-priority patent/US9506925B2/en
Application filed by Dragon Victory Dev Ltd filed Critical Dragon Victory Dev Ltd
Publication of AU2014399919A1 publication Critical patent/AU2014399919A1/en
Priority to AU2017232129A priority Critical patent/AU2017232129B2/en
Application granted granted Critical
Publication of AU2014399919B2 publication Critical patent/AU2014399919B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2014399919A 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer Ceased AU2014399919B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017232129A AU2017232129B2 (en) 2014-07-02 2017-09-21 Specific biomarker set for non-invasive diagnosis of liver cancer

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14/321,870 US9885718B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
US14/321,870 2014-07-02
US14/321,867 2014-07-02
US14/321,867 US9506925B2 (en) 2014-07-02 2014-07-02 Specific biomarker set for non-invasive diagnosis of liver cancer
PCT/US2014/049038 WO2016003479A1 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017232129A Division AU2017232129B2 (en) 2014-07-02 2017-09-21 Specific biomarker set for non-invasive diagnosis of liver cancer

Publications (2)

Publication Number Publication Date
AU2014399919A1 AU2014399919A1 (en) 2016-08-11
AU2014399919B2 true AU2014399919B2 (en) 2019-10-24

Family

ID=55019816

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014399919A Ceased AU2014399919B2 (en) 2014-07-02 2014-07-31 Specific biomarker set for non-invasive diagnosis of liver cancer
AU2017232129A Ceased AU2017232129B2 (en) 2014-07-02 2017-09-21 Specific biomarker set for non-invasive diagnosis of liver cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017232129A Ceased AU2017232129B2 (en) 2014-07-02 2017-09-21 Specific biomarker set for non-invasive diagnosis of liver cancer

Country Status (12)

Country Link
EP (1) EP3164711A4 (enExample)
JP (2) JP2017520763A (enExample)
KR (1) KR102086788B1 (enExample)
CN (2) CN107478842B (enExample)
AU (2) AU2014399919B2 (enExample)
CA (1) CA2939912C (enExample)
MY (2) MY179845A (enExample)
NZ (1) NZ722492A (enExample)
SG (1) SG11201606106SA (enExample)
TW (1) TWI700493B (enExample)
UY (1) UY36200A (enExample)
WO (1) WO2016003479A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106383231B (zh) * 2016-09-02 2020-03-17 四川大学 一种诊断肝癌的标记物组合及其应用
GB201619954D0 (en) * 2016-11-25 2017-01-11 Oncimmune Ltd Antibody assay
KR102175265B1 (ko) 2019-03-13 2020-11-06 충남대학교산학협력단 Txndc7을 포함하는 간세포암종 진단 또는 예후 예측용 바이오마커 조성물
CN110646615B (zh) * 2019-08-27 2021-07-13 南方医科大学 肝纤维化的生物学标志物、治疗靶点及其用途
WO2023282916A1 (en) 2021-07-09 2023-01-12 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
EP4179111B1 (en) 2020-07-10 2024-04-03 Guardant Health, Inc. Methods of detecting genomic rearrangements using cell free nucleic acids
CN113502328A (zh) * 2021-05-27 2021-10-15 深圳市人民医院 检测样本中标志物表达水平的试剂在制备用于检测或诊断乳腺癌的试剂盒中的应用
CN113777295B (zh) * 2021-09-15 2024-03-19 江南大学 用于检测肿瘤标志物pd-l1的高灵敏度量子点探针、制备方法及应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN114113611B (zh) * 2021-12-13 2023-07-14 郑州大学 一种用于肝癌诊断的生物标志物及检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049704A2 (en) * 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449562B1 (en) 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
US6893844B1 (en) * 1998-09-22 2005-05-17 Long Yu DNA encoding a new human hepatoma derived growth factor and producing method thereof
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
WO2003058201A2 (en) * 2001-12-31 2003-07-17 Quark Biotech, Inc. Methods for identifying marker genes for cancer
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP3960614B2 (ja) * 2003-08-31 2007-08-15 株式会社イムノディア 抗ペプチド抗体測定法とペプチドワクチンのワクチン候補選択方法
GB0406215D0 (en) * 2004-03-19 2004-04-21 Procure Therapeutics Ltd Prostate stem cell
CA2567987A1 (en) * 2004-06-18 2005-12-29 Gabriele Pestlin Use of protein pdx1 as a marker for breast cancer
JP5211315B2 (ja) 2006-07-25 2013-06-12 国立大学法人愛媛大学 腫瘍マーカ、腫瘍診断キットおよび腫瘍マーカの測定方法
JP5553603B2 (ja) * 2007-08-10 2014-07-16 学校法人兵庫医科大学 新規肝癌マーカー
US8512963B2 (en) * 2009-11-25 2013-08-20 The Johns Hopkins University Detection and quantitation of full-length thioredoxin (TRX) and truncated thioredoxin (TRX 80) in complex samples
US9523680B2 (en) * 2010-06-30 2016-12-20 Ambergen, Inc. Global Proteomic screening of random bead arrays using mass spectrometry imaging
JP5493130B2 (ja) 2010-08-25 2014-05-14 国立大学法人山口大学 自己抗体の検出方法
CA2827894A1 (en) * 2011-02-22 2012-08-30 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049704A2 (en) * 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex

Also Published As

Publication number Publication date
AU2017232129B2 (en) 2018-10-25
CA2939912A1 (en) 2016-01-07
JP2017520763A (ja) 2017-07-27
AU2014399919A1 (en) 2016-08-11
CA2939912C (en) 2019-04-16
KR20170021234A (ko) 2017-02-27
CN105319362B (zh) 2018-07-13
TWI700493B (zh) 2020-08-01
EP3164711A1 (en) 2017-05-10
CN107478842B (zh) 2020-10-16
CN105319362A (zh) 2016-02-10
WO2016003479A1 (en) 2016-01-07
TW201602579A (zh) 2016-01-16
NZ722492A (en) 2019-09-27
MY179845A (en) 2020-11-18
HK1224370A1 (zh) 2017-08-18
UY36200A (es) 2016-01-29
CN107478842A (zh) 2017-12-15
MY195045A (en) 2023-01-04
HK1248803A1 (zh) 2018-10-19
JP2020160082A (ja) 2020-10-01
KR102086788B1 (ko) 2020-03-09
EP3164711A4 (en) 2018-05-23
AU2017232129A1 (en) 2017-10-12
SG11201606106SA (en) 2016-08-30

Similar Documents

Publication Publication Date Title
AU2014399919B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
Jeong et al. Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1
JP5265140B2 (ja) 卵巣癌の検出方法及び検出用キット
US20200386761A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
JP6361943B2 (ja) 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット
US10620209B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
KR102617206B1 (ko) 췌장암 및 췌장관 내 유두상 점액성 종양의 마커
CN111323590B (zh) 抗TIF1γ-IgA与抗TIF1γ-IgG作为联合诊断标志物在肺癌诊断中的应用
US9885718B2 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
US10066020B2 (en) Methods of detecting cancer
RU2438135C1 (ru) Способ иммуноцитохимической оценки пролиферативного состояния лимфоцитов по характеру экспрессии c-концевого фрагмента белка b23/нуклеофозмина в реакции непрямой иммунофлюоресценции
KR101649591B1 (ko) 신규 급성백혈병의 진단용 마커
JP7432578B2 (ja) がんマーカーおよびその用途
JP5358808B2 (ja) 腫瘍マーカー、腫瘍診断キット、腫瘍マーカーの測定方法および腫瘍診断方法
Dai et al. Changes of serum tumor markers, immunoglobulins, TNF-α and hsCRP levels in patients with breast cancer and its clinical significance
WO2016143805A1 (ja) 膀胱がんの検出方法
HK1224370B (zh) 用於肝癌的无创诊断的特异性生物标志物组
HK1248803B (zh) 用於肝癌的无创诊断的特异性生物标志物组
JP2009192527A (ja) 癌マーカー及び癌細胞の検査方法
Brooks et al. Beyond PSA testing for prostate cancer: Better biomarkers are needed to ensure early and accurate detection and prognosis of prostate cancer.
JP2012225822A (ja) ＡＰＣ−ｂｉｎｄｉｎｇｐｒｏｔｅｉｎＥＢ１を用いた大腸癌の診断、治療法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired